Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and
etoposide(CE)and second-line therapy with topotecan has been given, patients with extensive
small cell lung cancer(ED-SCLC) still relapse and 2-year survival is less than 10%. There is
no standard treatment recommendation for this group of patients who failed to second-line
therapy and had good performance status. Apatinib has been approved as a second-line
treatment for advanced gastric cancer. Several phase III clinical studies of non small cell
lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less
toxic side effects and better patient tolerance. However, the clinical application of
apatinib in small cell lung cancer is still lack of evidence-based medicine. And this
clinical trial is designed to prospectively investigate the efficacy and safety of apatinib
in refractory or recurrent ED-SCLC patients in our center.